Browse News

Found 886 articles

• Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/24/2023

  Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2022, and provided a corporate update.

• Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting

  3/23/2023

  Galapagos NV publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting,to be held on Tuesday 25 April 2023, at 2:00 p.m., at the registered office of the company.

• Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions

  3/9/2023

  Iktos announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.

• Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors

  3/7/2023

  Artax Biopharma, Inc. today announces the Company has appointed Andre Hoekema, Ph.D., to the Company's Board of Directors.

• Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

  2/27/2023

  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that Rhythm’s Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V. (“Rhythm BV”), acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

• Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

  2/27/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.

• Galapagos announces full year 2022 results and outlook for 2023

  2/23/2023

  Galapagos NV reports 2022 results, supported by strong adoption of Jyseleca® across Europe, and provides outlook for 2023.

• Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

  2/9/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation(EBMT)-European Hematology Association (EHA)5thEuropean CAR T-cell Meeting in Rotterdam.

• Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

  2/8/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced the topline results from DIVERSITY, a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once daily, during induction and maintenance treatment ofbiologic-naïve and biologic-experienced patients with moderate to severe Crohn's disease (CD).

• Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event

  1/5/2023

  Ryvu Therapeutics announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® Panel Discussion entitled “European Partners Dream Big, Make Bold Progress” on Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time.

• Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Galapagos NV will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023.

• Galapagos announces changes to Executive Committee

  12/22/2022

  Galapagos NV announced changes in the Executive Committee effective 1 January 2023.

• Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

  12/22/2022

  Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the completion of its public offering of 4,764,674 Series J common shares (“Public Offering”).

• Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

  12/13/2022

  Galapagos NV and CellPoint presented encouraging initial data from the ongoing ATALANTA-1 Phase 1/2 study with GLPG5101 at the 64th Annual American Society of Hematology Congress taking place in New Orleans, Louisiana, from 10-13 December.

• Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

  12/11/2022

  Ryvu Therapeutics announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 and its selective PIM/FLT3 inhibitor SEL24 at the 64th American Society of Hematology Annual Meeting & Exposition, which is being held on December 10–13, 2022, in New Orleans, Louisiana.

• Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/23/2022

  Ryvu Therapeutics today announced third quarter 2022 financial results and provided a corporate update.

• Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

  11/11/2022

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders.

• Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

  11/8/2022

  Galapagos NV will present new dataon filgotinibat the American College of Rheumatology Convergence 2022 meetingtaking place in Philadelphia, Pennsylvania from 10-14 November 2022.

• Inflammatory Bowel Disease Treatment Market Size to Surpass USD 40.8 BN by 2030

  11/7/2022

  The global Inflammatory Bowel Disease Treatment market size was estimated at USD 25.20 billion in 2022 and is expected to surpass around USD 40.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2022 to 2030.

• 

  Galapagos Turfs Fibrosis, Kidney Disease Focus in “Forward Faster” Plan

  11/4/2022

  Galapagos' new "forward faster" strategy will see the departure of the company’s fibrosis and kidney disease programs and 200 staff members.